Wall Street Zen upgraded shares of Entero Therapeutics (NASDAQ:GRDX – Free Report) from a strong sell rating to a sell rating in a report released on Saturday,Wall Street Zen reports.
Entero Therapeutics Stock Performance
Shares of Entero Therapeutics stock opened at $5.35 on Friday. The business has a 50-day moving average of $4.13 and a 200-day moving average of $3.59. Entero Therapeutics has a 1-year low of $1.87 and a 1-year high of $6.93.
Entero Therapeutics Company Profile
Entero Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for gastrointestinal diseases. The company’s research programs are designed to address conditions involving intestinal inflammation, gluten intolerance and digestive enzyme deficiencies.
Its pipeline has included latiglutenase, an oral enzyme therapy being developed for celiac disease, as well as niclosamide-based therapies for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.
Featured Stories
- Five stocks we like better than Entero Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
